Marginal Zone B-Cell Lymphoma
Showing 1 - 25 of >10,000
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,
Completed
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +8 more
- PI3K inhibitor BKM120
- +3 more
-
Atlanta, Georgia
- +1 more
Jun 27, 2022
Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,
Active, not recruiting
- Adult Grade III Lymphomatoid Granulomatosis
- +23 more
- autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
OR Regimen Refractory Marginal Zone Lymphoma Trial (obrutinib, rituximab)
Not yet recruiting
- OR Regimen Refractory Marginal Zone Lymphoma
- obrutinib, rituximab
- (no location specified)
Nov 12, 2023
MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,
Active, not recruiting
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +9 more
- BTK inhibitor PCI-32765
- +5 more
-
Columbus, OhioOhio State University Medical Center
Jun 27, 2022
Marginal Zone Lymphoma Trial (Mosunetuzumab + Lenalidomide, - Rituximab + Lenalidomide (28-days cycles, - Rituximab +
Not yet recruiting
- Marginal Zone Lymphoma
- Mosunetuzumab + Lenalidomide
- +3 more
- (no location specified)
Aug 16, 2023
Marginal Zone Lymphoma Trial in Tianjin (Obinutuzumab, lenalidomide)
Recruiting
- Marginal Zone Lymphoma
- Obinutuzumab, lenalidomide
-
Tianjin, Tian, ChinaInstitute of Hematology & Blood Diseases Hospital
Apr 27, 2023
Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)
Not yet recruiting
- Follicular Lymphoma
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Mar 13, 2023
Lymphoma Trial (Ultra Low Dose 4 Gy Radiation)
Not yet recruiting
- Lymphoma
- Ultra Low Dose 4 Gy Radiation
- (no location specified)
Jun 30, 2023
Marginal Zone Lymphoma Trial ([68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose)
Not yet recruiting
- Marginal Zone Lymphoma
- (no location specified)
Nov 6, 2023
Molecular Taxonomy of Nodal Marginal Zone Lymphoma
Not yet recruiting
- Nodal Marginal Zone Lymphoma
-
Paris, France
- +2 more
Jan 17, 2023
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)
Recruiting
- Follicular Lymphoma
- +4 more
- Obinutuzumab
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in
Completed
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- +20 more
- panobinostat
- +6 more
-
Scottsdale, Arizona
- +1 more
May 6, 2022
Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Marginal Zone Lymphoma (MZL)
- Odronextamab
- +2 more
-
Chiang Mai, ThailandChiang Mai University
Nov 20, 2023
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- +6 more
- (no location specified)
Apr 12, 2023
Indolent Non-hodgkin Lymphoma Trial in Shanghai (IBI376)
Active, not recruiting
- Indolent Non-hodgkin Lymphoma
-
Shanghai, ChinaRuijin hospital, school of medicine, Shanghai jiao tong universi
Oct 3, 2022
B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)
Recruiting
- B-cell Lymphoma
- +5 more
- Cyclophosphamide
- +3 more
-
Louisville, KentuckyNorton Cancer Institute
Jan 24, 2023
Lymphoma Trial in Milan (clarithromycin, oral, high dose)
Completed
- Lymphoma
- clarithromycin, oral, high dose
-
Milan, ItalyDpt of OncoHematology - Fondazione Centro San Raffaele del Monte
Aug 10, 2022
Relapsed/Refractory Marginal Zone Lymphoma Trial in China (Orelabrutinib, Lenalidomide, Rituximab)
Not yet recruiting
- Relapsed/Refractory Marginal Zone Lymphoma
- Orelabrutinib
- +3 more
-
Guangzhou, Guangdong, China
- +10 more
Oct 8, 2023
Marginal Zone B-cell Lymphoma Trial in Korea, Republic of (bendamustine plus rituximab)
Completed
- Marginal Zone B-cell Lymphoma
- bendamustine plus rituximab
-
Jeonju, Jeollabuk-do, Korea, Republic of
- +10 more
Sep 23, 2021
Relapsed/Refractory Marginal Zone Lymphoma Trial in Westbury (Zanubrutinib, Rituximab, Lenalidomide)
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Marginal Zone Lymphoma
- Zanubrutinib
- +3 more
-
Westbury, New YorkClinical Research Alliance, Inc.
Nov 14, 2022
Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Seattle (Laboratory Biomarker
Active, not recruiting
- Follicular Lymphoma
- +2 more
- Laboratory Biomarker Analysis
- Pembrolizumab
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Dec 6, 2022
Splenic Marginal Zone Lymphoma Trial in Worldwide (Rituximab, Zanubrutinib)
Not yet recruiting
- Splenic Marginal Zone Lymphoma
-
Aarhus, Denmark
- +4 more
Feb 17, 2023
Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma Trial in New Haven, New Brunswick, Providence (Mosunetuzumab,
Recruiting
- Follicular Lymphoma
- +2 more
-
New Haven, Connecticut
- +2 more
Jul 14, 2022
Marginal Zone Lymphoma of Ocular Adnexal Trial in Italy (Doxycycline)
Active, not recruiting
- Marginal Zone Lymphoma of Ocular Adnexal
-
Messina, Italy
- +6 more
Nov 4, 2022